Trials / Completed
CompletedNCT02628223
180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma
A Randomized Trial of 180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 76 (actual)
- Sponsor
- Temple University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Selective laser trabeculoplasty (SLT) is a well-recognized way to lower eye pressure in treatment of glaucoma. This treatment is performed for 180 degrees or 360 degrees, and studies at academic centers have shown mixed results when comparing the success rates of 180 degrees or 360 degrees. Both protocols are now typically done by comprehensive ophthalmologists. However, there is no data that compares success rates of 180 degrees and 360 degrees in the community setting.
Detailed description
This study is designed as a prospective evaluation of the two treatment algorithms for SLT by measuring intraocular pressure (IOP) after treatment. The hypothesis is that 360 degrees of SLT will produce a greater reduction in IOP than 180 degrees of SLT at 3 months follow up.
Conditions
- Open Angle Glaucoma
- Ocular Hypertension
- Glaucoma, Open Angle, Pseudo-exfoliative
- Pigment Dispersion Syndrome
- Glaucoma
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Selective Laser Trabeculoplasty | The procedure uses light energy provided by a neodymium (Nd):Yttrium Aluminum Garnet (YAG) laser that is directed into the iridocorneal angle via a goniolens viewed through a standard slit lamp. |
| DEVICE | Neodymium:Yttrium Aluminum Garnet (YAG) laser | The procedure uses a 400 μm spot size of light energy provided by a low-energy, Q-switched, frequency-doubled (532 nm) neodymium (Nd):Yttrium Aluminum Garnet (YAG) laser with a short pulse duration of 3 nanoseconds that is directed into the iridocorneal angle via a goniolens viewed through a standard slit lamp. |
Timeline
- Start date
- 2014-09-01
- Primary completion
- 2017-12-01
- Completion
- 2017-12-01
- First posted
- 2015-12-11
- Last updated
- 2020-11-05
- Results posted
- 2020-11-05
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02628223. Inclusion in this directory is not an endorsement.